gvtcx

RMH - CAR-T Treatment

The Royal Marsden NHS Foundation Trust Published 24 Oct 2025 Find a Tender

key details

Statuscomplete
Proceduredirect
SME suitableYes
OCIDocds-h6vhtk-05d335

Award

SupplierValueDateStatus
not named £380,000 · pending

description

CAR-T treatment called Obecel developed to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL) which has recently become available to patients. The decision which treatment is most suitable applicable to a specific age group is a clinical one that would be decided by a Multi-Disciplinary Team (MDT). The product should meet strict NHS England standards for cryogenic storage and handling and RMH has such credentials.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
24 Oct 2025 Transparency notice (UK5) Procurement Act 2023 068116-2025

more from The Royal Marsden NHS Foundation Trust

all contracts from this buyer →

source

Published on Find a Tender. Contact details for named individuals are not reproduced on this site.